PMID- 29910724
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1663-4365 (Print)
IS  - 1663-4365 (Electronic)
IS  - 1663-4365 (Linking)
VI  - 10
DP  - 2018
TI  - Cdk5 Inhibitory Peptide Prevents Loss of Dopaminergic Neurons and Alleviates 
      Behavioral Changes in an MPTP Induced Parkinson's Disease Mouse Model.
PG  - 162
LID - 10.3389/fnagi.2018.00162 [doi]
LID - 162
AB  - Parkinson's disease (PD) is one of the most affected neurodegenerative diseases 
      in the world. Deregulation of cyclin-dependent kinase 5 (Cdk5) is believed to 
      play an important role in neurodegenerative diseases including PD. p25 is a 
      cleavage peptide of p35, a physiologic activator of Cdk5. p25 combines to Cdk5 
      and leads to the hyperactivity of Cdk5, which in turn hyperphosphorylates 
      downstream substrates and leads to neuroinflammation and apoptosis of neurons. 
      Previously, we have demonstrated that adeno-associated virus serotype-9 (AAV9) 
      mediated Cdk5 inhibitory peptide (CIP) inhibits the activity of Cdk5/p25 complex 
      and alleviates pathologic and behavioral changes in Alzheimer's disease mouse 
      model. In this study, we evaluated whether AAV9-CIP protected dopaminergic (DA) 
      neurons in 1-methyl-4-phe-nyl-1,2,3,6-tetrahydropyridine-probenecid (MPTP/p) 
      induced PD mouse model. The data showed that administration of AAV9-CIP by 
      intracerebroventricular injection 1 week before MPTP/p exposure protected loss of 
      DA neurons in substantia nigra compact of the model mice. Importantly, AAV9-CIP 
      also alleviated the motor and anxiety-like symptoms of the disease animals. In 
      summary, AAV9 mediated CIP might be a potential intervention for PD.
FAU - He, Rongni
AU  - He R
AD  - Department of Neurology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
AD  - Department of Neurology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Huang, Wei
AU  - Huang W
AD  - Department of Neurology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Huang, Yaowei
AU  - Huang Y
AD  - Department of Neurology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Xu, Miaojing
AU  - Xu M
AD  - Department of Neurology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Song, Pingping
AU  - Song P
AD  - Department of Neurology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Huang, Yinwei
AU  - Huang Y
AD  - Department of Neurology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Xie, Huifang
AU  - Xie H
AD  - Department of Neurology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Hu, Yafang
AU  - Hu Y
AD  - Department of Neurology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20180601
PL  - Switzerland
TA  - Front Aging Neurosci
JT  - Frontiers in aging neuroscience
JID - 101525824
PMC - PMC5992349
OTO - NOTNLM
OT  - AAV9
OT  - CIP
OT  - MPTP
OT  - Parkinson's disease
OT  - cyclin-dependent kinase 5
EDAT- 2018/06/19 06:00
MHDA- 2018/06/19 06:01
PMCR- 2018/01/01
CRDT- 2018/06/19 06:00
PHST- 2018/01/10 00:00 [received]
PHST- 2018/05/15 00:00 [accepted]
PHST- 2018/06/19 06:00 [entrez]
PHST- 2018/06/19 06:00 [pubmed]
PHST- 2018/06/19 06:01 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.3389/fnagi.2018.00162 [doi]
PST - epublish
SO  - Front Aging Neurosci. 2018 Jun 1;10:162. doi: 10.3389/fnagi.2018.00162. 
      eCollection 2018.